文献速递浆细胞疾病

多发性骨髓瘤可测量残留病评估的未来潜在方向

Potential future direction of measurable residual disease evaluation in multiple myeloma.
PubMed 文献 · Blood · 2023-01-01

本文综述多发性骨髓瘤可测量残留病(MRD)评估的现状与未来方向。MRD阴性超越严格完全缓解,新一代流式与测序可检测百万分之一骨髓瘤细胞;文章讨论MRD作为生存替代终点、疗效评估及适应性早期挽救治疗的概念,并分析其在新诊断、复发难治、适合与不适合移植及标危高危患者中的适用性。

要点

  • MRD阴性较严格完全缓解更深,可能改善结局并最终通向治愈。
  • 新一代流式与测序检测限可达百万健康细胞中检出1个骨髓瘤细胞。
  • MRD可作为临床与试验中的共同主要终点及生存替代指标。

核心结论

  • 多发性骨髓瘤仍不可治愈且复发率高,更深更持久的缓解与结局改善相关并可能最终通向治愈。
  • 治疗目标应超越严格完全缓解,朝向分子和流式完全缓解即可测量残留病阴性。
  • MRD可作为临床和试验中的共同主要终点、生存替代指标,并用于评估疗效及指导适应性应答驱动和早期挽救治疗。

研究设计与样本

  • 综述,总结当前可测量残留病相关数据并讨论其未来潜在应用。

主要发现

  • 完全缓解伴与不伴MRD患者结局差异已被证实超过20年。
  • 检测技术从多参数流式细胞术发展到新一代流式与新一代测序,检测限可达百万健康细胞中检出1个骨髓瘤细胞。
  • 当前完全缓解定义欠佳,治疗目标应超越严格完全缓解。

关键数值与推荐

  • MRD阴性定义为超越严格完全缓解的分子和流式完全缓解。
  • 新一代流式与测序检测限为百万健康细胞中检出1个骨髓瘤细胞。

临床怎么用

  • 作者讨论MRD作为临床和试验中的共同主要终点及生存替代指标。
  • 作者讨论MRD用于评估疗效及指导适应性应答驱动和早期挽救治疗。
  • 作者讨论上述概念在新诊断与复发难治骨髓瘤、适合与不适合移植患者及标危与高危疾病中的适用性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma remains an incurable disease plagued by high relapse rates. Deeper and more sustainable responses, however, have been consistently shown to improve outcomes and could eventually pave the way to achieving a cure. Our understanding of disease response has surpassed complete response (CR), because the current definitions are suboptimal, and the treatment goal should aim even beyond stringent CR, toward molecular and flow CR, that is, measurable residual disease (MRD) negativity. It has been more than 20 years since the discrepancy in the outcome between patients in CR with and without MRD has been demonstrated, and the field has come a long way from multiparameter flow cytometry to next-generation flow and next-generation sequencing, able to detect up to a limit of detection of a single myeloma cell from 1 million healthy counterparts. This review aims to summarize the current available data regarding MRD but also its potential future use as a coprimary outcome both in clinical and trial settings as a survival surrogate as well as its use to evaluate treatment efficacy and for adaptive response-based and early-rescue therapy. Furthermore, we discuss whether these concepts are applicable in different settings (eg, newly diagnosed and relapsed/refractory myeloma, patients who are eligible and ineligible for tansplant, and standard- and high-risk disease).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mohty M, Avet-Loiseau H, Malard F, et al. Potential future direction of measurable residual disease evaluation in multiple myeloma. Blood. 2023. PMID: 37471603. doi:10.1182/blood.2023020284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。